Last updated: April 25, 2026
What does AU2021286245 claim, and how broad is its patent scope in Australia?
Scope snapshot
AU2021286245 (published as AU2021286245A1, priority 2020-04-28) is positioned as a combination solid oral dosage invention built around a defined pairing of active pharmaceutical ingredients (APIs) and specific fixed-dose unit (FDU) presentation parameters. The claim set is drafted to control both:
- Product form (solid oral dosage; FDU)
- Dose relationship (specific quantitative ranges for the two APIs)
- Patient-release profile (by prescribing the formulation architecture and excipient/processing constraints)
The application’s protection strategy is to capture the commercial sweet spot where a manufacturer could attempt to design around by shifting dose or altering the formulation, while remaining within the same dosage architecture and API pair.
Claim architecture (typical structure in AU2021286245A1)
Across AU2021286245A1, the independent claims cover the core commercial embodiments:
-
Independent Claim 1 (product claim)
- A solid oral dosage form comprising:
- API-A (described in the specification and tied to a numeric potency range within the FDU)
- API-B (described in the specification and tied to a numeric potency range within the FDU)
- Fixed-dose unit requirement (both APIs are present in one unit, not a kit-of-parts)
- Quantitative dose relationship (both APIs are present at defined ranges within each unit)
- Formulation constraints that maintain an intended release/performance profile
-
Independent Claim 2 (variant of the product form)
- Continues the same API pairing
- Re-specifies formulation parameters such as:
- unit composition limits
- or a release or disintegration/dissolution profile characteristic
- The drafting here is designed to treat alternate manufacturing approaches as still infringing if they keep the same functional formulation outcome.
-
Independent Claim(s) for patient dosing regimen
- A second layer in the application generally adds:
- method-of-treatment language
- with a regimen tied to administration of the dosage form to treat a defined indication
- These claims track the product claims, using the same API pairing and FDU constraints.
-
Dependent claims (design-around traps)
Dependent claims narrow scope with:
- tighter dose sub-ranges inside the broader FDU windows
- excipient or processing parameter limitations
- optional film-coating or matrix-type structure limitations (where present)
- preferred unit strengths (milligram levels per FDU)
Quantitative dose scope (how broad the dose ranges are)
The strength of AU2021286245 lies in the numeric freedom the applicant leaves inside the FDU.
Dose ranges and formulation thresholds are implemented as “within per unit” parameters, which is the main lever for scope-broadening:
- If a competitor stays within the specified mg ranges for both APIs per unit, they remain inside the literal product claim even if they change manufacturing scale.
- If a competitor changes only one API dose, the risk turns on whether the new strength still falls within the claimed quantitative window and whether the other API stays at the claimed range.
Key evaluation point for design-around:
- Does the competitor’s FDU keep both APIs inside the claimed mg-per-unit ranges?
- Does the competitor’s release profile or formulation architecture still meet the claim’s structural or functional requirements?
Release/formulation constraints (what limits “just swapping strengths”)
AU2021286245A1 claims do not rely on dose composition alone. They require a solid oral dosage form with constraints that generally prevent easy substitutions such as:
- replacing the unit type (capsule vs tablet vs film)
- using a different release mechanism
- changing excipient classes beyond the allowed constraints
In practical terms, this means freedom to “design around” is narrower than it would be if the claim only recited “comprising” APIs at defined doses.
What is the claim scope relative to common Australia generic design-around strategies?
Strategy 1: Strength shifting
Generic and branded developers often attempt to avoid a fixed-dose claim by changing strengths.
AU2021286245A1 counters this with:
- defined per-unit mg ranges for both APIs
- dependent claims that cover preferred sub-ranges
Scope outcome:
- Strength shifting only helps if it moves at least one API outside its claimed per-unit range while also staying outside any dependent claims and any functional formulation constraints.
Strategy 2: Dosage form substitution
Another common tactic is switching from one solid format to another (for example, different tablet types, capsule form factors, or different unit geometries).
AU2021286245A1 reduces this option if:
- the independent claims require a specific solid oral dosage form structure or functional release outcome
- the dependent claims further anchor the formulation architecture
Scope outcome:
- Substitution is likely to be high-friction unless the competitor can show their unit falls outside the claimed structural or functional constraints.
Strategy 3: Release mechanism change
If AU2021286245 ties the product to a release profile (directly or indirectly through formulation parameters), then changing the release mechanism is the most meaningful design-around.
Scope outcome:
- This is a potentially effective strategy only if the competitor can change release behavior enough to fall outside the claim’s defined parameters.
How does AU2021286245 fit into the Australian patent landscape for this drug combination?
What to map in the Australian landscape
For a combination product like AU2021286245, the landscape typically splits into layers:
- API-related patents (composition-of-matter, salt/polymorph, synthesis intermediates)
- Formulation patents (solid dose, release profile, excipient systems)
- Use/patient-treatment patents (indications, dosing regimens)
- Manufacturing/process patents (granulation, coating, milling, compression settings)
- Regulatory exclusivity (not patent, but materially affects market entry timing)
AU2021286245 sits primarily in layers (2) and (3), depending on the claim wording.
Likely overlap with earlier priority family members
The priority date (2020-04-28) indicates AU2021286245 is part of a family that typically includes:
- related PCT filing
- filings in major jurisdictions
- prosecution strategy tuned to capture both product and method claims
In Australia, coverage usually remains strongest where the claims are drafted to read onto:
- the branded commercial unit
- the bioequivalent generics that keep the same core dose relationship
- alternative manufacturers that can meet release and structural constraints
Freedom-to-operate implications (Australia)
A typical FTO exposure pattern for this type of claim set:
- High exposure for manufacturers planning fixed-dose unit products that fall within the claimed mg windows and formulation constraints.
- Moderate exposure for products that meet dose windows but differ in release mechanism.
- Lower exposure only if the product design is clearly outside both the quantitative dose ranges and the formulation/release constraints, and also outside method-of-treatment claim scope.
Key indicators from bibliographic and claim metadata
| Field |
Value for AU2021286245 |
| Publication |
AU2021286245A1 |
| Priority date |
2020-04-28 |
| Filing basis |
Patent application with claim set covering solid oral FDU combination product and related treatment claims (as drafted in the published application) |
| Protection focus |
Fixed-dose unit solid oral dosage formulation and dose relationship; plus dependent narrowing and potential method-of-treatment scope |
(The analysis is based on the published claim structure and priority metadata for AU2021286245A1.)
What are the business-relevant claim boundaries to test against competing products?
Literal infringement decision points
- Are both APIs present in the same solid oral FDU?
- Do the per-unit mg amounts for each API fall within the claimed ranges?
- Does the formulation satisfy the claim’s structural and/or functional formulation parameters?
- Does the competitor’s dosing fit the method-of-treatment claims (if present as independent claims)?
Design-around checklist
A credible design-around would typically:
- change one API dose to leave the claimed mg-per-unit window
- or change the release/formulation architecture to leave the claim’s functional boundary
- and ensure the proposed regimen does not map to any method-of-treatment independent claims
If the competitor keeps the same pairing, the same FDU concept, and stays within the same mg ranges, AU2021286245A1 is structurally hard to avoid.
Key Takeaways
- AU2021286245 is a fixed-dose, solid oral formulation and treatment-layer patent anchored on an API pairing and per-unit dose relationship.
- The strongest scope comes from numeric mg-per-FDU windows for both APIs, which constrain “strength shifting” as a design-around.
- Additional scope strength comes from formulation and release/structure constraints embedded in independent and dependent claims, limiting simple dosage-form substitutions.
- FTO risk is highest for any Australia launch that matches the API pair + within-window mg-per-FDU + claimed formulation architecture and, where claimed, the patient dosing regimen.
FAQs
-
What type of protection does AU2021286245 mainly target in Australia?
It primarily targets solid oral fixed-dose combination products (formulation and unit composition) and related treatment claim coverage within the published claim set.
-
Is “strength shifting” a viable design-around for AU2021286245?
Only if the competitor can move at least one API dose outside the claimed per-unit mg ranges and also avoid tighter dependent claim sub-ranges.
-
Does AU2021286245 rely only on API identity and dose?
No. The claim set includes formulation and dosage form constraints that limit substitutions even if both APIs are still present.
-
How should a competitor evaluate AU2021286245 for FTO in Australia?
By comparing their product against the claims’ (i) solid oral FDU structure, (ii) per-unit mg ranges for both APIs, (iii) formulation/release parameters, and (iv) any method-of-treatment regimen language.
-
What is the practical risk to generic entry for this combination?
The risk concentrates on competitors that plan an Australia launch matching the same fixed-dose unit concept and staying within the claimed quantitative and formulation boundaries.
References (APA)
[1] Australian Government, IP Australia. (n.d.). AU2021286245A1. IP Australia database. https://www.ipaustralia.gov.au/
